Table 2 Risk factors for interruption in treatment among Adolescence patients on ART in Tanga region

Age group (yrs)

10 – 14

15 – 19

Reference

1.88 (1.77–1.99)

Reference

1.43 (1.23–1.66)

Sex

Female

Male

Reference

0.87 (0.82–0.92)

Reference

2.47 (1.62–3.77)

District

Handeni

Kilindi

Korogwe

Lushoto

Mkinga

Muheza

Pangani

Tanga

1.13 (1.02–1.26)

0.70 (0.57–0.85)

1.31 (1.19–1.44)

0.99 (0.89–1.11)

0.73 (0.62–0.86)

6.70 (6.06–7.41)

0.69 (0.57–0.88)

Reference

1.18 (0.93–1.50)

1.33 (0.92–1.91)

0.55 (0.44–0.69)

0.35 (0.26–0.45)

0.63 (0.45–0.90)

2.01 (1.52–2.65)

0.79 (0.52–1.19)

Reference

BMI group, kg/m²

<18.5

18.5 – <25

25-<30

30+

0.66 (0.62–0.72)

Reference

1.34 (0.97–1.87)

1.38 (1.16–1.65)

0.85 (0.71–1.04)

Reference

3.80 (2.00–5.20)

0.62 (0.28–1.35)

WHO Stage

I

II

III

IV

Reference

0.79 (0.70–0.90)

1.50 (1.36–1.64)

2.17 (1.93–2.45)

Reference

0.50 (0.38–0.66)

0.86 (0.70–1.05)

2.47 (1.91–3.21)

Pregnant Status

No

Yes

Reference

1.09 (0.71–1.68)

Marita Status

Cohabiting

Divorced

Married

Single

Widow

0.50 (0.45–0.56)

3.03 (1.60–5.75)

1.64 (1.37–1.95)

Reference

1.70 (1.20–2.47)

0.82 (0.65–1.03)

5.03 (1.60–5.75)

1.59 (0.99–2.56)

Reference

0.50 (0.20–1.28)

ART duration (yrs)

<=1

>1

2.27 (2.10–2.45)

Reference

0.68 (0.54–0.87)

Reference

Adherence

Good

Poor

Reference

1.51 (1.31–1.73)

Reference

1.12 (0.75–1.66)

TB history

No

Yes

Reference

1.85 (1.30–2.63)

Reference

1.72 (0.58–4.67)

Regimen

First line

Second line

Reference

4.89 (4.10–5.85)

Reference

0.50 (0.34–0.76)

Viral load suppression

Suppressed

Not suppressed

Reference

1.58 (1.45–1.73)

Reference

1.04 (0.83–1.30)

Dolutegravir (DTG) related drug

No

Yes

5.38 (4.24–6.53)

Reference

6.67 (3.36–7.04)

Reference